Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ipca Adds To API Business By Acquiring Ramdev

Executive Summary

India’s Ipca is boosting its API business with a deal to acquire local firm Ramdev Chemical for INR1.1bn in cash.

You may also be interested in...



Ipca Takes Full Ownership Of Bayshore

Ipca has struck a deal to take full ownership of US firm Bayshore Pharmaceuticals by acquiring the remaining 20% stake that it did not already own.

Ipca takes control of US player Bayshore

Ipca Laboratories has paid just under US$10.3 million in cash for 80% of the share capital in US generics player Bayshore Pharmaceuticals. The Indian company said that acquiring the majority stake in sales and marketing firm Bayshore through its wholly-owned US subsidiary Ipca Pharmaceuticals would “enable the firm to commercialise its registered generic drug products in the US market through this entity”.

API gains boost Ipca’s sales

A 27% rise in turnover from active pharmaceutical ingredients (APIs) contributed to Ipca Laboratories increasing its group turnover by just over a fifth to Rs8.68 billion (US$121 million) in its financial first quarter ended 30 June 2018. Exports of APIs climbed by 17% to Rs1.58 billion, while the Indian company’s domestic sales of bulk drugs shot up by two-thirds to Rs600 million (see Figure 1).

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB140281

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel